scholarly journals Enrichment of circulating melanoma cells (CMCs) using negative selection from patients with metastatic melanoma

Oncotarget ◽  
2014 ◽  
Vol 5 (9) ◽  
pp. 2450-2461 ◽  
Author(s):  
Powrnima Joshi ◽  
Barbara Jacobs ◽  
Adeeb Derakhshan ◽  
Lee R. Moore ◽  
Paul Elson ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Negative Selection ◽  
Melanoma Cells

Abstract 1454: Evaluation of negative selection strategy for enrichment of circulating melanoma cells (CMCs) from patients with metastatic melanoma.

2013 ◽  
Author(s):  
Powrnima Joshi ◽  
Barbara Jacobs ◽  
Adeeb Derakhshan ◽  
Lee R. Moore ◽  
Pierre Triozzi ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Negative Selection ◽  
Melanoma Cells ◽  
Selection Strategy

Effect of statins on NF-κB in human metastatic melanoma cells

2013 ◽  
Vol 1 (Suppl. 1) ◽  
pp. A3.7
Author(s):  
Stefan Salzmann
Keyword(s):  
Metastatic Melanoma ◽  
Melanoma Cells

Investigating the photodynamic efficacy of chlorin e6 by millisecond pulses in metastatic melanoma cells

2020 ◽  
pp. 107728
Author(s):  
Julita Kulbacka ◽  
Grzegorz Chodaczek ◽  
Joanna Rossowska ◽  
Anna Szewczyk ◽  
Jolanta Saczko ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Melanoma Cells ◽  
Chlorin E6

Hypoxic miRNAs expression are different between primary and metastatic melanoma cells

Gene ◽  
2021 ◽  
pp. 145552
Author(s):  
Yasunori Hino ◽  
Md Mahfuzur Rahman ◽  
Yu-Chang Lai ◽  
Al Asmaul Husna ◽  
Hui-wen Chen ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Melanoma Cells ◽  
Mirnas Expression

scholarly journals Deregulated FASN Expression in BRAF Inhibitor-Resistant Melanoma Cells Unveils New Targets for Drug Combinations

Cancers ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 2284
Author(s):  
Serena Stamatakos ◽  
Giovanni Luca Beretta ◽  
Elisabetta Vergani ◽  
Matteo Dugo ◽  
Cristina Corno ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Metastatic Melanoma ◽  
Mutant Cell ◽  
Braf Inhibitor ◽  
Cancer Cell Line ◽  
Melanoma Cells ◽  
Melanoma Progression ◽  
Increased Sensitivity ◽  
Resistant Cells

Metabolic changes promoting cell survival are involved in metastatic melanoma progression and in the development of drug resistance. In BRAF-inhibitor resistant melanoma cells, we explored the role of FASN, an enzyme involved in lipogenesis overexpressed in metastatic melanoma. Resistant melanoma cells displaying enhanced migratory and pro-invasive abilities increased sensitivity to the BRAF inhibitor PLX4032 upon the molecular targeting of FASN and upon treatment with the FASN inhibitor orlistat. This behavior was associated with a marked apoptosis and caspase 3/7 activation observed for the drug combination. The expression of FASN was found to be inversely associated with drug resistance in BRAF-mutant cell lines, both in a set of six resistant/sensitive matched lines and in the Cancer Cell Line Encyclopedia. A favorable drug interaction in resistant cells was also observed with U18666 A inhibiting DHCR24, which increased upon FASN targeting. The simultaneous combination of the two inhibitors showed a synergistic interaction with PLX4032 in resistant cells. In conclusion, FASN plays a role in BRAF-mutated melanoma progression, thereby creating novel therapeutic opportunities for the treatment of melanoma.

Endothelin-3 Is Produced by Metastatic Melanoma Cells and Promotes Melanoma Cell Survival

2008 ◽  
Vol 12 (2) ◽  
pp. 64-70 ◽  
Author(s):  
Liren Tang ◽  
Mingwan Su ◽  
Yi Zhang ◽  
Wency Ip ◽  
Magdalena Martinka ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Signal Transduction Pathway ◽  
Melanoma Cells ◽  
Transduction Pathway ◽  
Paracrine Factor ◽  
Study Results ◽  
Autocrine Stimulation ◽  
Endothelin 3 ◽  
Adult Skin

Background: Endothelin-3 (ET-3) is an essential paracrine factor for the proliferation, migration, and survival of embryonic melanocytes during fetal development. Its expression is tightly regulated, being completely turned off in adult skin. Objective: In this study, results are presented that demonstrate abnormal expression of ET-3 by metastatic melanoma cells in both tissue biopsies and cell culture. Further, in vitro experiments showed that metastatic melanoma cells have the capacity to respond to ET-3 stimulation by increasing survival. Conclusion: Therefore, an abnormal autocrine stimulation pathway involving ET-3 is present in metastatic melanoma cells. Blocking this signal transduction pathway may prove useful for the treatment of metastatic melanoma.

Vaccination With Irradiated, Autologous Melanoma Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor by Adenoviral-Mediated Gene Transfer Augments Antitumor Immunity in Patients With Metastatic Melanoma

2003 ◽  
Vol 21 (17) ◽  
pp. 3343-3350 ◽  
Author(s):  
Robert Soiffer ◽  
F. Stephen Hodi ◽  
Frank Haluska ◽  
Ken Jung ◽  
Silke Gillessen ◽  
...  
Keyword(s):  
Gene Transfer ◽  
Metastatic Melanoma ◽  
Tumor Cells ◽  
Antitumor Immunity ◽  
Melanoma Cells ◽  
Colony Stimulating Factor ◽  
Gm Csf ◽  
Macrophage Colony Stimulating Factor ◽  
Macrophage Colony ◽  
Stimulating Factor

Purpose: Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) by retroviral-mediated gene transfer generates potent antitumor immunity in patients with metastatic melanoma. Further clinical development of this immunization scheme requires simplification of vaccine manufacture. We conducted a phase I clinical trial testing the biologic activity of vaccination with irradiated, autologous melanoma cells engineered to secrete GM-CSF by adenoviral-mediated gene transfer.Patients and Methods: Excised metastases were processed to single cells, transduced with a replication-defective adenoviral vector encoding GM-CSF, irradiated, and cryopreserved. Individual vaccines were composed of 1 × 106, 4 × 106, or 1 × 107tumor cells, depending on overall yield, and were injected intradermally and subcutaneously at weekly and biweekly intervals.Results: Vaccines were successfully manufactured for 34 (97%) of 35 patients. The average GM-CSF secretion was 745 ng/106cells/24 hours. Toxicities were restricted to grade 1 to 2 local skin reactions. Eight patients were withdrawn early because of rapid disease progression. Vaccination elicited dense dendritic cell, macrophage, granulocyte, and lymphocyte infiltrates at injection sites in 19 of 26 assessable patients. Immunization stimulated the development of delayed-type hypersensitivity reactions to irradiated, dissociated, autologous, nontransduced tumor cells in 17 of 25 patients. Metastatic lesions that were resected after vaccination showed brisk or focal T-lymphocyte and plasma cell infiltrates with tumor necrosis in 10 of 16 patients. One complete, one partial, and one mixed response were noted. Ten patients (29%) are alive, with a minimum follow-up of 36 months; four of these patients have no evidence of disease.Conclusion: Vaccination with irradiated, autologous melanoma cells engineered to secrete GM-CSF by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

scholarly journals Targeted photodynamic therapy treatment of in vitro A375 metastatic melanoma cells

Oncotarget ◽  
2019 ◽  
Vol 10 (58) ◽  
pp. 6079-6095 ◽  
Author(s):  
Channay Naidoo ◽  
Cherie Ann Kruger ◽  
Heidi Abrahamse
Keyword(s):  
Photodynamic Therapy ◽  
Metastatic Melanoma ◽  
Melanoma Cells ◽  
Targeted Photodynamic Therapy ◽  
Therapy Treatment

SENSITIVITY OF HUMAN METASTATIC MELANOMA CELLS TO THE ESTER ANALOG OF RAPAMYCIN, CCI-779

2004 ◽  
Vol 78 ◽  
pp. 729
Author(s):  
E Maellaro ◽  
M A. Valentini ◽  
B Del Bello ◽  
M Carmellini
Keyword(s):  
Metastatic Melanoma ◽  
Melanoma Cells
Sign in / Sign up

Export Citation Format

Share Document